1-Jahres-Chart (nicht börsennotiert)
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MERUS LABS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MPH HEALTH CARE | 24,000 | 0,00 % | EQS-News: MPH Health Care AG: EBIT steigt auf 55,6 Mio. Euro. Das Eigenkapital (Net Asset Value) steigt um 49,3 Mio. Euro auf 300,3 Mio. Euro, dies entspricht 70,14 Euro je Aktie. Die Eigenkapitalquote steigt auf 94,85 %. | EQS-News: MPH Health Care AG
/ Schlagwort(e): 9-Monatszahlen/Quartalsergebnis
EBIT steigt auf 55,6 Mio. Euro. Das Eigenkapital (Net Asset Value) steigt um 49,3 Mio. Euro auf 300... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 8,616 | +0,42 % | EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
| AMARIN | 0,540 | +2,86 % | AMARIN CORP PLC - 8-K, Current Report | ||
| SELLAS LIFE SCIENCES | 1,172 | +3,72 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update | - Pre-specified Events to Trigger Interim Analysis of Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Remains on Track for Q4 2024 - - Data from the Phase 2a Trial of SLS009 in Relapsed/Refractory... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 332,50 | -0,33 % | 3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move | ||
| CATALYST PHARMACEUTICALS | 19,880 | -3,54 % | Catalyst Pharmaceuticals Insider Trades Send A Signal | ||
| ANI PHARMACEUTICALS | 53,00 | +2,91 % | ANI PHARMACEUTICALS INC - 8-K, Current Report | ||
| CANNABIS SATIVA | - | - | New Study Suggests Cannabis Sativa Extracts Could Help Prevent Or Reverse Sun Damage | ||
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals Receives FDA Approval for Generic Vyvanse | Northvale, New Jersey--(Newsfile Corp. - November 18, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture... ► Artikel lesen | |
| TITAN PHARMACEUTICALS | 0,001 | 0,00 % | Titan Pharmaceuticals, Inc.: Titan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd. | NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan") today announced that it has entered into a Merger and Contribution and Share Exchange Agreement (the... ► Artikel lesen | |
| BLUM HOLDINGS | - | - | Blum Holdings CEO Sabas Carrillo erwirbt Aktien im Wert von 7.992 US-Dollar | ||
| BMP PHARMA TRADING | 3,000 | -33,33 % | PTA-News: B.M.P. Pharma Trading AG: Steigerung der Rentabilität im 1. Halbjahr 2024 - Rentabilitätsanstieg EBIT um 15,5% | DJ PTA-News: B.M.P. Pharma Trading AG: Steigerung der Rentabilität im 1. Halbjahr 2024 - Rentabilitätsanstieg EBIT um 15,5%
Unternehmensmitteilung für den Kapitalmarkt
Norderstedt (pta/02.10.2024/16:48)... ► Artikel lesen | |
| THERIVA BIOLOGICS | 1,290 | +1,57 % | Theriva Biologics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| KAZIA THERAPEUTICS | 5,770 | +4,34 % | Kazia Therapeutics Limited: Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring ... | Treatment with 45mg paxalisib and radiotherapy demonstrated 67% partial response (PR)
Over two-thirds of the patients at maximum tolerated dose (MTD) achieved intracranial response which compares favorably... ► Artikel lesen | |
| ALLERGY THERAPEUTICS | 0,060 | 0,00 % | Allergy Therapeutics - Notice of 2024 Annual General Meeting |
MERUS LABS INTERNATIONAL INC gehört der Branche Pharma an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MERUS LABS INTERNATIONAL INC finden Sie auf Wallstreet Online.
